HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 281, Issue 29, 20464-20473, July 21, 2006

This Article Full Text Full Text (PDF) Supplemental Data All Versions of this Article: 281/29/20464    most recent M603387200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zupnick, A. Articles by Prives, C. Search for Related Content PubMed PubMed Citation Articles by Zupnick, A. Articles by Prives, C. Social Bookmarking                      What's this?

Mutational Analysis of the p53 Core Domain L1 Loop^*

From the Department of Biological Sciences, Columbia University, New York, New York 10027

The p53 tumor suppressor gene acquires missense mutations in over 50% of human cancers, and most of these mutations occur within the central core DNA binding domain. One structurally defined region of the core, the L1 loop (residues 112-124), is a mutational "cold spot" in which relatively few tumor-derived mutations have been identified. To further understand the L1 loop, we subjected this region to both alanine- and arginine-scanning mutagenesis and tested mutants for DNA binding in vitro. Select mutants were then analyzed for transactivation and cell cycle analysis in either transiently transfected cells or cells stably expressing wild-type and mutant proteins at regulatable physiological levels. We focused most extensively on two p53 L1 loop mutants, T123A and K120A. The T123A mutant p53 displayed significantly better DNA binding in vitro as well as stronger transactivation and apoptotic activity in vivo than wild-type p53, particularly toward its pro-apoptotic target AIP1. By contrast, K120A mutant p53, although capable of strong binding in vitro and wild-type levels of transactivation and apoptosis when transfected into cells, showed impaired activity when expressed at normal cellular levels. Our experiments indicate a weaker affinity for DNA in vivo by K120A p53 as the main reason for its defects in transactivation and apoptosis. Overall, our findings demonstrate an important, yet highly modular role for the L1 loop in the recognition of specific DNA sequences, target transactivation, and apoptotic signaling by p53.

Received for publication, April 10, 2006 , and in revised form, May 9, 2006.

^* This work was supported by NCI Grant CA77742 from the National Institutes of Health. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. 1 and 2.

¹ To whom correspondence should be addressed. Tel.: 212-854-2557; Fax: 212-865-8246; E-mail: clp3{at}columbia.edu.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Lokshin, Y. Li, C. Gaiddon, and C. Prives p53 and p73 display common and distinct requirements for sequence specific binding to DNA Nucleic Acids Res., January 12, 2007; 35(1): 340 - 352. [Abstract] [Full Text] [PDF]

				H. Tidow, D. B. Veprintsev, S. M. V. Freund, and A. R. Fersht Effects of Oncogenic Mutations and DNA Response Elements on the Binding of p53 to p53-binding Protein 2 (53BP2) J. Biol. Chem., October 27, 2006; 281(43): 32526 - 32533. [Abstract] [Full Text] [PDF]

				A. C. Joerger, H. C. Ang, and A. R. Fersht From the Cover: Structural basis for understanding oncogenic p53 mutations and designing rescue drugs PNAS, October 10, 2006; 103(41): 15056 - 15061. [Abstract] [Full Text] [PDF]